Tasigna (nilotinib) is a pharmaceutical drug commonly used to treat Philadelphia chromosome-positive chronic myeloid leukemia. Numerous studies published in prominent medical journals worldwide show Tasigna side effects include irreversible and life threatening conditions that can result in limb amputation, cardiovascular problems, and death. Tasigna causes atherosclerosis, a dangerous thickening of the arterial walls, which in turn results in peripheral arterial disease (PAD). Causing the arteries to narrow, Tasigna can lead to infections and tissue death requiring amputation, coronary artery disease, stroke, and death. The American public has never been warned of Tasigna atherosclerosis.
Novartis International AG, the Swiss pharmaceutical company responsible for manufacturering and marketing Tasigna, has been aware of the risk for Tasigna atherosclerosis since at least 2011 but remained silent. Novartis issued a Tasigna side effects warning in Canada in 2013 in conjunction with the Canadian health service, but never warned doctors or patients in the United States.
Meanwhile, Novartis engaged in illegal misbranding and payment of kickbacks for Tasigna; the company settled a U.S. Department of Justice Tasigna lawsuit in 2015 by paying $390 million. Novartis engaged in an aggressive marketing campaign aimed at promoting Tasigna over competing leukemia treatments, touting false claims of the drug's superiority and omitting Tasigna atherosclerosis warning information. Tasigna is among the ten most popular cancer drugs in the world, yielding more than $1.7 billion in sales in 2016.
If you or a loved one has suffered from Tasigna side effects or complications, you may be eligible to receive compensation through filing a Tasigna lawsuit. These Tasigna attorneys provide free, no-obligation case reviews to persons and family members who match this description. Our Tasigna lawyers have a strong track record of success in the realm of dangerous drug litigation. Should you choose to retain our Tasigna lawyers, there is never any fee unless we win compensation on your behalf.
Tasigna, a popular drug used to treat chronic myeloid leukemia, has been found to pose life-threatening risks to patients. Specifically, Tasigna causes severe and rapid-onset atherosclerosis which in turn causing peripheral arterial disease. On simple terms, Tasigna results in a swelling of the arteries which can lead to cardiovascular problems, limb amputation, and death.
Intended to provide treatment for chronic leukemia, Tasigna in fact introduces a new and significant danger. Patients and doctors in the United States have never been warned of Tasigna atherosclerosis, meaning thousands of patients have been exposed to a severe and life-threatening risk at no fault of their own. The manufacturer, Novartis, has been aware of the risk for severe Tasigna side effects for several years; instead of warning consumers, the company aggressively marketed its product as superior to other treatments. In 2015, Novartis became embroiled in a Tasigna lawsuit over illegal misbranding and promotion by monetary kickbacks; the company paid a settlement of $390 million to the U.S. Department of Justice.
Tasigna lawyers representing cases nationwide believe that persons and the families of persons harmed by Tasigna may be eligible for significant compensation through filing Tasigna atherosclerosis lawsuits against Novartis. This page provides full information about Tasigna side effects from national* Tasigna attorneys.
Tasigna is among the most popular cancer drugs in the world, garnering in excess of $1.7 billion during 2016. Tasigna is the brand name for nilotinib, a protein-tyrosine kinase inhibitor which blocks chemical enzymes in cancer cells in order to prevent cell growth and division. Tasigna is a product of Novartis AG Pharmaceutical, a giant pharmaceutical company based out of Switzerland. Tasigna was approved by the FDA in 2007, for the treatment of chronic myeloid leukemia. The drug was approved with a Black Box warning related to other Tasigna side effects; patients were not warned of the risk of Tasigna atherosclerosis and related complications.
Atherosclerosis is a condition that causes the artery walls to thicken. The thickening is caused by a buildup of white blood cells and the growth of a fibrofatty plaque.
When the arterial walls thicken, the channel where blood flows becomes narrowed. This condition is known as peripheral arterial disease (PAD). PAD most commonly affects the legs, but can also occur in other arteries. The lack of proper blood circulation which occurs as a result of Tasigna atherosclerosis is severe and irreversible, causes infections and tissue death, and may require one or more limb amputations. Coronary artery disease, stroke, and death are all possible outcomes of Tasigna atherosclerosis.
Evidence supporting the link between Tasigna and atherosclerosis has been published in more than a dozen studies in prominent medical journals in the United States, Canada and Europe. The first major Tasigna atherosclerosis research was published in 2011, finding that 25% of patients experienced vascular problems as a result of the drug and 16% suffered from peripheral arterial disease. Among the nine Tasigna atherosclerosis studies published in 2013 was a postmarket review from the FDA. Taking into account Tasigna atherosclerosis research from the U.S., Europe and Canada, as well as adverse event reports filed in the U.S., the FDA wrote its findings "strongly suggest an association between nilotinib (Tasigna) and PAOD (peripheral arterial occlusive disease)". At that time, an FDA Tasigna atherosclerosis warning was added to the drug's packaging information.
When the drug's warning label was updated in the United States to reflect a risk for Tasigna atherosclerosis, no formal FDA warning was issued. Due to this fact, most health care providers and patients were not aware of the new risk information. However, also in 2013, Novartis issued a Tasigna atherosclerosis warning in conjunction with the Canadian health agency, Health Canada. The Tasigna warning stated that cases of atherosclerosis and resulting complications had been detected in clinical trials and through post-market reporting. Clinicians were warned to test frequently for signs of the disease. Had this type of Tasigna atherosclerosis warning been made in the United States, many lives and much suffering would have been spared.
Our attorneys have experience in holding large corporations accountable when they've placed profits ahead of safety. Through settlements and winning verdicts, our attorneys have obtained millions for our clients. Let us help you today.
Filing a lawsuit will allow you to hold the pharmaceutical company accountable for damage it has caused you or a loved one, while also providing real compensation for your medical expenses, suffering and loss. Contact us today for a free consultation.
The national* Tasigna attorneys at Onder, Shelton, O'Leary & Peterson, LLC, are experts in the realm of product liability litigation for dangerous drugs. When American families have been harmed by the negligence or greed of a billion dollar pharmaceutical giant, we see it as our duty to pursue justice. In this case, the drug maker knowingly concealed Tasigna risk information from the American public, while simultaneously engaging in aggressive and unethical advertising and payment of illegal kickbacks to promote the drug. Our Tasigna lawyers believe persons who were harmed by Tasigna atherosclerosis or another Tasigna complication may be eligible for real compensation by filing a claim against Novartis.
Our experienced Tasigna lawyers have seen the aftereffects of numerous drug recalls. Aware of the gravity of Tasigna atherosclerosis lawsuits, this national* drug litigation law firm is offering its significant resources to provide clients with the best Tasigna attorney representation possible. These Tasigna lawyers will provide a free case review to persons and family members of persons who have been harmed by Tasigna. Never warned of the risk for Tasigna atherosclerosis, these individuals have suffered through no fault of their own. The Tasigna lawyers aim to achieve compensation for loss and suffering, while holding Novartis accountable for its actions.
We will represent all persons involved in a Tasigna lawsuit on a contingency basis, meaning there are never any legal fees unless we win compensation in your case. For a free no-obligation consultation please contact our firm; one of our national* Tasigna attorneys will contact you to answer any of your questions.
Onder, Shelton, O'Leary & Peterson, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O'Leary & Peterson has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others, and other law firms throughout the nation often seek its experience and expertise on complex litigation. For more information, visit www.OnderLaw.com or call 1-877-ONDER-LAW.
Essure is a contraceptive approved by the FDA as a form of permanent birth control. The complications associated with Essure have become so severe that its maker is halting all sales outside of the US. Essure complications include ectopic pregnancy, migration & expulsion, perforation or tear of pelvic organs including the uterus and colon. Many of the Essure complications require one or more surgeries, including hysterectomy, to remove it and repair internal organs.
Roundup weed killer, manufactured by Monsanto, uses a chemical called glyphosate, which the World Health Organization labeled as a probable carcinogen in 2015. Roundup is the most popular of all glyphosate-based herbicides. As little as 8 hours of Roundup exposure has been linked to an increased risk of non-Hodgkin lymphoma, multiple myeloma, and leukemia. Millions of gardeners, landscapers, farmers and others have been exposed to Roundup cancer risks.
Taxotere is a chemotherapy drug that has been widely used over the last two decades, for treating breast cancer among others. Although hair loss is a side effect of many chemotherapy treatments, hair loss for many Taxotere users is permanent. For some Taxotere users, the permanent hair loss is complete, other users have clumps of hair regrowth. Some people will regrow some or all of their hair after a number of years, others never regrow hair.